Literature DB >> 32574394

Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand.

Win M Han1, Donn J Colby2,3,4, Apichaya Khlaiphuengsin5, Tanakorn Apornpong1, Stephen J Kerr1,6,7, Sasiwimol Ubolyam1, Eugène Kroon2, Nittaya Phanuphak8, Sandhya Vasan3,4, Gail V Matthews7, Anchalee Avihingsanon1,9, Kiat Ruxrungtham1,10, Praphan Phanuphak1,2,8, Pisit Tangkijvanich5.   

Abstract

A rapidly emerging and highly concentrated hepatitis C virus (HCV) outbreak has recently been observed among both acute and chronic HIV-positive men who have sex with men (MSM) in Bangkok, Thailand. NS5B regions of the HCV genome were amplified using nested PCR and sequenced. Phylogenetic inference was constructed by Maximum Likelihood methods and clusters were identified with support and genetic distance thresholds of 85% and of 4.5%. Forty-eight (25 acute HIV and 23 chronic HIV) MSM with incident HCV infection were included in the analysis. HCV genotype (GT) was 85% GT 1a and 15% GT 3a or 3b. Median age at HCV diagnosis was 34 (interquartile range, 28-41) years. 83.3% (40/48) had history of syphilis infection and 36% (16/44) reported crystal methamphetamine use. Only 2 (4%) reported ever injecting drugs, both crystal methamphetamine. In the phylogenetic clustering analysis, 83% belonged to one of two clusters: one large (75%) and one small (8%) cluster. All clusters were GT 1a. MSM with acute HIV infection were more likely to be in a cluster (92%) than those with chronic infection (74%). HCV screening should be regularly performed for MSM in ART clinics, and offering direct-acting antiviral agents to all MSM with HCV infection might contain the HCV epidemic from expanding further.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV infection; men who have sex with men; molecular epidemiology; phylogenetic clustering; sexual transmission

Mesh:

Substances:

Year:  2020        PMID: 32574394     DOI: 10.1111/liv.14578

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Screening for Sexually Transmitted Infections During Hepatitis C Treatment to Predict Reinfection Among People With HIV.

Authors:  Lucas A Hill; Natasha K Martin; Francesca J Torriani; Sonia Jain; Huifang Qin; Wm Christopher Mathews; Edward R Cachay
Journal:  Open Forum Infect Dis       Date:  2020-12-30       Impact factor: 3.835

2.  Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: A cost effectiveness modelling study.

Authors:  Shreoshee Mukherjee; Donn Colby; Reshmie Ramautarsing; Stephanie Popping; Somchai Sriplienchan; Tanat Chinbunchorn; Nittaya Phanuphak; David van de Vijver
Journal:  J Virus Erad       Date:  2021-05-18

3.  Knowledge, attitude, and behaviors toward liver health and viral hepatitis-related liver diseases in Thailand.

Authors:  Pochamana Phisalprapa; Tawesak Tanwandee; Boon-Leong Neo; Shikha Singh
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

4.  Prevalence and the associated factors of hepatitis B and hepatitis C viral infections among HIV-positive individuals in same-day antiretroviral therapy initiation program in Bangkok, Thailand.

Authors:  Supanat Thitipatarakorn; Tanat Chinbunchorn; Jitsupa Peelay; Pich Seekaew; Sorawit Amatavete; Monsiri Sangsai; Tippawan Pankam; Anchalee Avihingsanon; Matthew Avery; Praphan Phanuphak; Reshmie Ramautarsing; Nittaya Phanuphak
Journal:  BMC Public Health       Date:  2022-01-20       Impact factor: 3.295

5.  The 'Viennese epidemic' of acute HCV in the era of direct-acting antivirals.

Authors:  David Chromy; David J M Bauer; Benedikt Simbrunner; Matthias Jachs; Lukas Hartl; Philipp Schwabl; Caroline Schwarz; Armin Rieger; Katharina Grabmeier-Pfistershammer; Michael Trauner; Peter Ferenci; Mattias Mandorfer; Michael Gschwantler; Thomas Reiberger
Journal:  J Viral Hepat       Date:  2022-03-15       Impact factor: 3.517

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.